Cellebrite DI Ltd. (NASDAQ:CLBT) Given Consensus Rating of “Buy” by Analysts

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have earned an average recommendation of “Buy” from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $18.57.

Several analysts recently commented on the company. Needham & Company LLC lifted their price objective on Cellebrite DI from $14.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Lake Street Capital boosted their price target on Cellebrite DI from $13.50 to $17.00 and gave the company a “buy” rating in a research note on Friday, August 16th. JPMorgan Chase & Co. upped their price target on shares of Cellebrite DI from $14.00 to $15.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Craig Hallum raised their price objective on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Finally, Bank of America upped their target price on shares of Cellebrite DI from $13.00 to $17.00 and gave the company a “buy” rating in a report on Friday, August 16th.

Cellebrite DI Stock Performance

NASDAQ CLBT opened at $17.91 on Thursday. The company has a market capitalization of $3.69 billion, a price-to-earnings ratio of -30.88, a PEG ratio of 2.50 and a beta of 1.52. The stock has a 50-day moving average of $17.18 and a 200 day moving average of $13.65. Cellebrite DI has a one year low of $6.36 and a one year high of $18.75.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings data on Thursday, August 15th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.02. Cellebrite DI had a negative net margin of 28.51% and a positive return on equity of 5,902.06%. The firm had revenue of $95.70 million during the quarter, compared to analysts’ expectations of $91.94 million. During the same period in the previous year, the company earned $0.05 earnings per share. The firm’s quarterly revenue was up 24.8% on a year-over-year basis. On average, equities analysts predict that Cellebrite DI will post 0.31 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellebrite DI

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLBT. Janney Montgomery Scott LLC increased its stake in shares of Cellebrite DI by 240.1% in the first quarter. Janney Montgomery Scott LLC now owns 45,300 shares of the company’s stock worth $502,000 after purchasing an additional 31,981 shares in the last quarter. Capstone Investment Advisors LLC purchased a new stake in Cellebrite DI in the 1st quarter worth $870,000. GSA Capital Partners LLP raised its holdings in Cellebrite DI by 574.0% during the first quarter. GSA Capital Partners LLP now owns 286,930 shares of the company’s stock valued at $3,179,000 after acquiring an additional 244,357 shares during the period. Quantbot Technologies LP raised its holdings in Cellebrite DI by 97.7% during the first quarter. Quantbot Technologies LP now owns 124,199 shares of the company’s stock valued at $1,376,000 after acquiring an additional 61,365 shares during the period. Finally, SG Americas Securities LLC lifted its position in shares of Cellebrite DI by 34.8% in the first quarter. SG Americas Securities LLC now owns 51,881 shares of the company’s stock valued at $575,000 after acquiring an additional 13,392 shares in the last quarter. Institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.